Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-02-12 7:58 pm Sale | 2020-12-31 | 13G | Therapeutics Acquisition Corp. RACA | BIOTECHNOLOGY VALUE FUND L P | 954,996 6.800% | -45,004 (-4.50%) | Filing History |
| 2021-02-12 7:23 pm Purchase | 2020-12-31 | 13G | Regulus Therapeutics Inc. RGLS | BIOTECHNOLOGY VALUE FUND L P | 705,046 9.990% | 495,376 (+236.26%) | Filing History |
| 2021-02-12 6:52 pm Sale | 2020-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | BIOTECHNOLOGY VALUE FUND L P | 3,499,346 10.000% | -17,505 (-0.50%) | Filing History |
| 2021-02-12 6:47 pm Purchase | 2020-12-31 | 13G | SUNESIS PHARMACEUTICALS INC CO SNSS | BIOTECHNOLOGY VALUE FUND L P | 1,814,308 9.980% | 1,814,308 (New Position) | Filing History |
| 2021-02-12 5:16 pm Purchase | 2020-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | BIOTECHNOLOGY VALUE FUND L P | 3,710,689 7.400% | 894,299 (+31.75%) | Filing History |
| 2021-02-12 5:03 pm Purchase | 2020-12-31 | 13G | Genocea Biosciences, Inc. GNCA | BIOTECHNOLOGY VALUE FUND L P | 5,285,549 9.990% | 2,123,881 (+67.18%) | Filing History |
| 2021-02-12 4:25 pm Sale | 2020-12-31 | 13G | Sutro Biopharma, Inc. STRO | BIOTECHNOLOGY VALUE FUND L P | 1,854,162 4.100% | -514,230 (-21.71%) | Filing History |
| 2021-02-12 4:22 pm Purchase | 2020-12-31 | 13G | Repare Therapeutics Inc. RPTX | BIOTECHNOLOGY VALUE FUND L P | 2,972,191 8.100% | 1,027,645 (+52.85%) | Filing History |
| 2021-02-12 4:20 pm Sale | 2020-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS | BIOTECHNOLOGY VALUE FUND L P | 70,020 9.990% | -3,390 (-4.62%) | Filing History |
| 2021-02-12 4:18 pm Sale | 2020-12-31 | 13G | Ovid Therapeutics Inc. OVID | BIOTECHNOLOGY VALUE FUND L P | 4,522,051 6.900% | -733,250 (-13.95%) | Filing History |
| 2021-02-12 4:16 pm Purchase | 2020-12-31 | 13G | Merus N.V. MRUS | BIOTECHNOLOGY VALUE FUND L P | 5,805,571 19.960% | 815,000 (+16.33%) | Filing History |
| 2021-02-12 4:15 pm Sale | 2020-12-31 | 13G | Kezar Life Sciences, Inc. KZR | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -203,979 (Position Closed) | Filing History |
| 2021-02-12 4:13 pm Sale | 2020-12-31 | 13G | Galmed Pharmaceuticals Ltd. GLMD | BIOTECHNOLOGY VALUE FUND L P | 9,998 8.400% | -182 (-1.79%) | Filing History |
| 2021-02-12 4:11 pm Purchase | 2020-12-31 | 13G | Forte Biosciences, Inc. FBRX | BIOTECHNOLOGY VALUE FUND L P | 53,770 9.990% | 10,171 (+23.33%) | Filing History |
| 2021-02-12 4:09 pm Sale | 2020-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | BIOTECHNOLOGY VALUE FUND L P | 2,898,797 9.990% | -22,380 (-0.77%) | Filing History |
| 2021-02-12 4:06 pm Purchase | 2020-12-31 | 13G | Cidara Therapeutics, Inc. CDTX | BIOTECHNOLOGY VALUE FUND L P | 223,075 9.990% | 54,637 (+32.44%) | Filing History |
| 2021-02-11 5:29 pm Sale | 2020-12-31 | 13G | MEI Pharma, Inc. MEIP | BIOTECHNOLOGY VALUE FUND L P | 279,466 4.900% | -64,856 (-18.84%) | Filing History |
| 2021-02-11 5:27 pm Purchase | 2020-12-31 | 13G | CytomX Therapeutics, Inc. CTMX | BIOTECHNOLOGY VALUE FUND L P | 5,576,471 12.100% | 950,060 (+20.54%) | Filing History |
| 2021-02-11 5:25 pm Sale | 2020-12-31 | 13G | Calithera Biosciences, Inc. CALA | BIOTECHNOLOGY VALUE FUND L P | 218,062 6.200% | -136,470 (-38.49%) | Filing History |
| 2021-02-11 5:23 pm Sale | 2020-12-31 | 13G | Molecular Templates, Inc. MTEM | BIOTECHNOLOGY VALUE FUND L P | 184,075 5.500% | -56,481 (-23.48%) | Filing History |